一种研究性喹诺酮、甘氨环素、糖肽、链阳菌素和恶唑烷酮单独及联合对耐万古霉素屎肠球菌的体外活性。
In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
作者信息
Mercier R C, Penzak S R, Rybak M J
机构信息
Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, College of Pharmacy and Allied Health Professions, Wayne State University, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 1997 Nov;41(11):2573-5. doi: 10.1128/AAC.41.11.2573.
Abstract
We evaluated the in vitro activities of clinafloxacin, CL331,002, LY333328, quinupristin dalfopristin, and eperezolid (formerly known as U-100,592) against four strains of enterococci. All regimens tested resulted in the growth inhibition of each isolate. Against the three clinafloxacin-susceptible strains, clinafloxacin tested alone was the most active treatment, decreasing the bacterial inoculum by more than 3 log10 CFU/ml after 24 h in time-kill curve studies.
摘要
我们评估了克林沙星、CL331,002、LY333328、奎奴普丁-达福普汀和依哌唑胺（原名U-100,592）对四种肠球菌菌株的体外活性。所有测试方案均导致每种分离株的生长受到抑制。在对三种对克林沙星敏感的菌株进行的时间-杀菌曲线研究中，单独使用克林沙星是最有效的治疗方法，24小时后可使细菌接种量减少超过3个对数10 CFU/ml。
相似文献
1
In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Nov;41(11):2573-5. doi: 10.1128/AAC.41.11.2573.
2
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
3
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
4
[Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
Enferm Infecc Microbiol Clin. 1999 Aug-Sep;17(7):335-9.
5
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
J Antimicrob Chemother. 1997 May;39 Suppl A:33-9. doi: 10.1093/jac/39.suppl_1.33.
6
Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Dec;41(12):2749-53. doi: 10.1128/AAC.41.12.2749.
7
Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
J Antimicrob Chemother. 1997 May;39 Suppl A:23-8. doi: 10.1093/jac/39.suppl_1.23.
8
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
9
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
10
Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1994 Jul;38(7):1668-70. doi: 10.1128/AAC.38.7.1668.
引用本文的文献
1
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.
2
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12. doi: 10.1128/AAC.46.8.2606-2612.2002.
3
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2001 Mar;45(3):706-9. doi: 10.1128/AAC.45.3.706-709.2001.
4
Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.
Curr Infect Dis Rep. 1999 Jun;1(2):148-152. doi: 10.1007/s11908-996-0022-8.
5
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
6
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
Antimicrob Agents Chemother. 2000 Nov;44(11):3017-21. doi: 10.1128/AAC.44.11.3017-3021.2000.
7
Oxazolidinones: a review.
Drugs. 2000 Jan;59(1):7-16. doi: 10.2165/00003495-200059010-00002.
8
Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1999 Dec;43(12):2873-6. doi: 10.1128/AAC.43.12.2873.
9
Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
Antimicrob Agents Chemother. 1999 Nov;43(11):2776-9. doi: 10.1128/AAC.43.11.2776.
10
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.
Antimicrob Agents Chemother. 1999 Oct;43(10):2513-6. doi: 10.1128/AAC.43.10.2513.
本文引用的文献
1
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.
Antimicrob Agents Chemother. 1995 Dec;39(12):2832-4. doi: 10.1128/AAC.39.12.2832.
2
Initial clinical experience with clinafloxacin in the treatment of serious infections.
Drugs. 1995;49 Suppl 2:488-91. doi: 10.2165/00003495-199500492-00145.
3
The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci.
J Infect Dis. 1993 May;167(5):1220-3. doi: 10.1093/infdis/167.5.1220.
4
An overview of nosocomial infections, including the role of the microbiology laboratory.
Clin Microbiol Rev. 1993 Oct;6(4):428-42. doi: 10.1128/CMR.6.4.428.
5
Genetics and mechanisms of glycopeptide resistance in enterococci.
Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71. doi: 10.1128/AAC.37.8.1563.
6
Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1994 Jul;38(7):1668-70. doi: 10.1128/AAC.38.7.1668.
7
Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium.
J Infect Dis. 1995 Jan;171(1):106-12. doi: 10.1093/infdis/171.1.106.
8
In-vitro activity of two glycylcyclines against enterococci resistant to other agents.
J Antimicrob Chemother. 1995 Jun;35(6):877-81. doi: 10.1093/jac/35.6.877.
9
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.
Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81. doi: 10.1128/AAC.32.8.1278.
10
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.
J Clin Microbiol. 1988 Jul;26(7):1287-91. doi: 10.1128/jcm.26.7.1287-1291.1988.
Zotero 插件